\
&
Contact us
\
&
Contact us
Published on | 4 years ago
ProgrammesIs your SME looking to embrace digital innovation? Connect with a supplier from the HUBCAP platform and receive tailormade support and services to co-create and experiment with CPS & MBD tools.
The HUBCAP initiative aim at upgrading the capacity of SMEs to leverage Model-Based Design (MBD) technology in Cyber Physical Systems (CPS) and ultimately deliver new products and services in multiple application domains. HUBCAP provides services and technical expertise and offers financial support for European SMEs to experiment in highly innovative, cross-border experiments.
At the moment the "experiment" call is open (until 2 Feb 2022). Eligible applications need to come from consortia of 2 SME's, where MBD CPS users/adopters will work with MBD CPS providers and experiment with MBD tools to implement these digital solutions in their products/services.
What your consortium will receive:
More information about the Experiment call can be found on https://www.hubcap.eu/open-calls
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
